Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
CELESTICA INC
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-80.8% vs price
Base Case (Median)
-74.8% vs price
Bull Case (75th pct.)
-50.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $68.46 | -80.2% | High (40%) |
| PE Comparable | $243.49 | -29.5% | Medium (25%) |
| Growth Trajectory DCF | $519.00 | 50.2% | Medium (20%) |
| Graham Number | $64.52 | -81.3% | Low (10%) |
| EV/EBITDA | $102.06 | -70.5% | Medium (20%) |
| EV/FCF | $86.92 | -74.8% | Medium (20%) |
| Earnings Power Value | $41.42 | -88.0% | Medium (50%) |
Based on 7 out of 7 methods, CLS appears overvalued at the current price of $345.51. The base case fair value of $86.92 implies 74.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.